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a transient period (8–12 days: Brambrink
et al., 2008; Stadtfeld et al., 2008). To-
gether, these findings suggest that nonin-
tegrating reprogramming methods may
be developed to provide transient overex-
pression of the transcription factors, which
will positively impact the ability to translate
iPS technology into therapies.
To begin to determine the origin of the
cell that gives rise to iPS colonies, Aoi
et al. (2008) used a lineage-tracing strate-
gy that identifies cells that, at some time,
have expressed the hepatic gene albu-
min. Their results indicate that liver-de-
rived iPS cells were almost all positive
for this reporter, suggesting that lineage-
committed cells can be reprogrammed
to an ES-like state. However, although
albumin is expressed in mature hepato-
cytes and liver progenitors, it could con-
ceivably have been activated during the
reprogramming process in vitro. To con-
clusively demonstrate that iPS cells arise
from terminally differentiated cells and
not rare stem cells, populations with
differentiation-associated genomic rear-
rangements, such as lymphocytes, will
need to be examined.
Although the hypothesis that iPS cells
arise from a rare stem cell remains possi-
ble until an unambiguously genetically
marked cell can be reprogrammed to indi-
cate the differentiation state of the donor
cell, Yamanaka’s latest studies suggest
that the low efficiency of reprogramming
is not a result of directed insertional muta-
genesis and that factor-induced reprog-
ramming is a universal process that is
not restricted to particular cell types.
Given that the overall efficiency of revert-
ing early reprogramming intermediates
into iPS cells is still low (Brambrink et al.,
2008; Stadtfeld et al., 2008), transcription
factor-induced reprogramming must re-
quire rare stochastic, likely epigenetic,
events. Analyzing subpopulations of iPS
intermediates from multiple tissues via
genome-wide approaches for factor bind-
ing and chromatin changes should reveal
important molecular events that occur
during this cascade. Such insights may
lead to safer, more efficient reprogram-
ming methods that will be necessary to
translate iPS cells into therapeutic tools.
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Cancer stem cells (CSCs) are a subpopulation of cancer cells that possess characteristics, including self-
renewal, associated with normal stem cells. In this issue of Cell Stem Cell, Wong et al. (2008) define a core
embryonic stem cell (ESC)-like gene expression program that may be important for CSC function in multiple
epithelial cancers.
Increasing evidence suggests that path-
ways and properties associated with nor-
mal stem cells are important for cancer
development. The link between genes im-
portant for normal stem cell development
and cancer is most clearly established
in hematopoietic malignancies, based
largely on the study of chromosomal
translocations identified in leukemias and
lymphomas. An extensive body of work
has demonstrated that these transloca-
tions often involve genes that play critical
roles in normal hematopoietic stem cell
(HSC) biology (reviewed in Orkin and
Zon, 2008). Human acute myelogenousCell Stem Cell 2, April 2008 ª2008 Elsevier Inc. 297
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neity and harbor subpopulations (often re-
ferred to as leukemia stem/initiating cells)
capable of extensive proliferation, self-
renewal, and increased frequency of tu-
mor formation, and appear to establish
a developmental hierarchy similar to
that observed in normal hematopoiesis
(Wang and Dick, 2005). Recent effort has
focused on isolating these leukemia stem
cells and examining the extent to which
they are similar to normal stem cells. Stud-
ies have demonstrated that certain murine
and human leukemia stem cells not only
are globally most similar to differentiating
myeloid populations but also exhibit gene
expression programs/pathways normally
associated with HSCs (Jamieson et al.,
2004; Krivtsov et al., 2006; Somervaille
and Cleary, 2006). Thus, in some hemato-
poietic cancers, differentiated progeny
appear to activate gene expression pro-
grams normally restricted to the stem cell
population of that tissue. The extent to
which stem cell programs are important
in solid tumors, and in particular in tumors
derived from epithelial cells, has been less
clear.
The present work by Wong and col-
leagues (Wong et al., 2008) uses a gene
module map (Segal et al., 2004) tool to
assay for the presence of stem cell pro-
grams in tumors of epithelial origin (Fig-
ure 1A). The initial step in their approach
was to identify gene sets that are coor-
dinately regulated in various cell types.
Some 3000 mouse gene sets were
compiled from various previous studies,
including gene expression profiles, ChIP-
chip results, RNAi experiments, and func-
tional annotations, such as those found
in Gene Ontology databases. The gene
sets were then assessed for coordinate
regulation by comparing expression data
obtained from mouse ESCs, adult tissue
stem cells (including neural stem cells
[NSCs], HSCs, retinal stem cells, neural
crest stem cells, hair bulge stem cells,
and mammary stem cells), and a number
of differentiated cell types. Using this
approach, they identified a shared subset
of genes termed ‘‘ESC-like’’ that clus-
tered ESCs together with NSCs, fetal liver
HSCs, and retinal stem cells. Clustering
away from these populations was the
majority of adult tissue stem cells, includ-
ing HSCs, neural crest stem cells, hair
bulge stem cells, and mammary stem
cells. This group shared a distinct subset
of genes that were termed the ‘‘adult tis-
sue stem’’ module. Interestingly, when
the approach was repeated with data de-
rived from studies of human cells, 335
genes were found to significantly overlap
between mouse and human ESC-like
modules. This subset was subsequently
defined as the ‘‘core’’ ESC-like gene
module.
In addition to defining the ESC-like
module, the authors demonstrated that
this gene expression program is activated
in multiple human cancers but repressed
innormal tissues. In order tostudywhether
expression of the ESC-like module might
have clinical implications for human can-
cers, 295 primary samples of stage I and
II breast cancers and 71 stage I and II
lung adenocarcinoma samples were ex-
amined. The analysis revealed a positive
correlation between activation of the ESC-
like module and poor tumor differentiation
status, increased risk of metastasis, and
a worse outcome in both sets of human
tumors. The authors then examined a
CSC-enriched subpopulation of breast
cancer cells shown previously to express
a gene expression signature that is corre-
lated with more aggressive clinical behav-
ior (Liu et al., 2007). The ESC-like signature
was detected in the CSC-enriched
CD44+CD24/low subpopulation of hu-
man breast cancers. Thus, it appears the
ESC-like module is expressed by certain
human tumors and that cancer stem cells
may be at least partially responsible for the
presence of this signature in bulk tumors.
Of note, increased expression of the ESC-
like profile correlates with a worse clinical
outcome, raising the possibility of its utility
as a prognostic tool.
Having identified the ESC-like signature
as potentially important for human tu-
mors, the authors switched their focus to
identifying potential mechanisms of sig-
nature activation. A computational screen
of cis-regulatory motifs identified c-Myc
as a potential regulator of the ESC-like
Figure 1. An ESC-like Program in Epithelial Cancer Stem Cells
(A) Certain adult tissue stem cells share a transcriptional program with ESCs, termed an ESC-like program.
Comparing the mouse and human ESC-like programs reveals 335 overlapping genes. The overlapping set
is used to define a ‘‘core’’ ESC-like program, a large subset of which has been identified as c-Myc targets.
(B) c-Myc expression can activate the ESC-like program in keratinocytes and lead to the development of
a tumor-forming population, possibly by inducing a cancer stem cell population.298 Cell Stem Cell 2, April 2008 ª2008 Elsevier Inc.
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module genes have been previously iden-
tified as c-Myc targets (http://www.
myc-cancer-gene.org/) (Figure 1A). Strik-
ingly, c-Myc, but not Src, b-catenin,
E2F3, or Ras, was able to activate the
ESC-like transcriptional program in adult
mammary epithelial cells and primary hu-
man fibroblasts. Next, Wong et al. (2008)
assessed an in vivo model of human tu-
mor development. Consistent with results
in cultured cells, c-Myc expression also
activated the ESC-like module in tumors
initiated by expression of c-Myc, Ras,
and IkBa in primary human keratinocytes.
Finally, the frequency of tumor initiating
cells in tumors generated by the com-
bined expression of c-Myc, Ras, and
IkBa was greater than in tumors derived
by expression of E2F3, Ras, and IkBa,
suggesting that c-Myc expression pro-
motes both activation of the ESC-like pro-
gram and development of cancer stem
cells in this system (Figure 1B).
The demonstration that an ESC-like
program is found in multiple human can-
cers, and that activation of this program
can be driven by c-Myc during conversion
of primary human cells to tumor-forming
populations, is particularly relevant to
ongoing efforts designed to study cancer
stem cell development. Growing evidence
strongly supports the hypothesis that
stem cell gene expression programs are
activated during leukemia stem cell devel-
opment. Wong et al. now provide
evidence that stem cell programs are
also relevant during epithelial cancerstem cell development and imply that
similar mechanisms may be relevant for
many cancers. An intriguing possibility
that arises from the present module map
analysis is that hematopoietic malignan-
cies are a result of activation of ‘‘lineage-
specific’’ stem cell programs, whereas
epithelial tumors may be more a result of
activation of ESC-like programs. This sep-
aration of hematopoietic and epithelial tu-
mors based on ‘‘lineage-specific stem
cell’’ programs versus the ‘‘ESC-like’’
module raises the question of which pat-
tern, if any, is apparent in other malignan-
cies, such as sarcomas. The functional
significance of the activation of various
stem cell pathways/programs in multiple
cancer stem cell populations clearly re-
mains to be determined.
Finally, the concept that activation of
stem cell programs can influence can-
cer stem cell development has important
implications for efforts to initiate cellular
reprogramming of somatic cells into in-
duced pluripotent stem (iPS) cells (Taka-
hashi and Yamanaka, 2006). As dis-
cussed, c-Myc can activate an ESC-like
program during the conversion of kerati-
nocytes to cancer stem cells (Wong
et al., 2008). However, c-Myc is also an
important, if expendable, reprogramming
factor that enhances the formation of iPS
cells from fibroblasts (reviewed in Knoep-
fler, 2008). Together, these findings sug-
gest that the processes of reprogram-
ming and cancer stem cell induction
may engage overlapping programs. This
possibility highlights the importance ofCell Stestudies designed to define the transcrip-
tional and signaling networks involved in
normal and cancer stem cell develop-
ment. With a better understanding of
these processes, it may become possible
to target cancer stem cells while not
heavily impeding normal stem cell func-
tion and also to develop cellular reprog-
ramming methods for use in regenerative
medicine without undue risk of cancer
stem cell development.
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